| Literature DB >> 33200360 |
Chien-Jen Chen1, San-Lin You2, Wan-Lun Hsu3, Hwai-I Yang3, Mei-Hsuan Lee4, Hui-Chi Chen3, Yun-Yuan Chen5, Jessica Liu6,7, Hui-Han Hu8, Yu-Ju Lin4, Yu-Ju Chu9, Yen-Tsung Huang10, Chun-Ju Chiang11, Yin-Chu Chien3.
Abstract
Seven viruses including the Epstein-Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), Kaposi's sarcoma herpes virus (KSHV), human immunodeficiency virus, type-1 (HIV-1), human T cell lymphotrophic virus, type-1 (HTLV-1), and human papillomavirus (HPV) have been classified as Group 1 human carcinogens by the International Agency for Research on Cancer (IARC). The conclusions are based on the findings of epidemiological and mechanistic studies. EBV, HPV, HTLV-1, and KSHV are direct carcinogens; HBV and HCV are indirect carcinogens through chronic inflammation; and HIV-1 is an indirect carcinogen through immune suppression. Some viruses may cause more than one cancer, while some cancers may be caused by more than one virus. However, only a proportion of persons infected by these oncogenic viruses will develop specific cancers. A series of studies have been carried out to assess the viral, host, and environmental cofactors of EBV-associated nasopharyngeal carcinoma, HBV/HCV-associated hepatocellular carcinoma, and HPV-associated cervical carcinoma. Persistent infection, high viral load, and viral genotype are important risk predictors of these virus-caused cancers. Risk calculators incorporating host and viral risk predictors have been developed for the prediction of long-term risk of hepatocellular carcinoma, nasopharyngeal carcinoma and cervical cancer. These risk calculators are useful for the triage and clinical management of infected patients. Both clinical trials and national programs of immunization, antiviral therapy and screening have demonstrated a significant reduction in the incidence of cancers caused by HBV, HCV, and HPV. Future research on gene-gene and gene-environment interactions of oncogenic viruses and the human host using large-scale longitudinal studies with serial measurements of biosignatures are in urgent need.Entities:
Keywords: Cancer; EBV; Epidemiology; HBV; HCV; HIV; HPV; HTLV-I; KSHV
Mesh:
Year: 2021 PMID: 33200360 DOI: 10.1007/978-3-030-57362-1_2
Source DB: PubMed Journal: Recent Results Cancer Res ISSN: 0080-0015